Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target of $46.0, a high estimate of $53.00, and a low estimate of $41.00. Witnessing a positive shift, the current average has risen by 0.26% from the previous average price target of $45.88.

In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4)

Shares of Bristol Myers Squibb Co. BMY shed 1.00% to $49.49 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.04% to 41,606.18. The stock's fall snapped a two-day winning streak.

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.